The Man Van: A pilot study of using mobile targeted case-finding to address health inequalities in prostate cancer.
early diagnosis
health inequalities
mobile testing
prostate cancer
prostate‐specific antigen
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
04 Sep 2024
04 Sep 2024
Historique:
revised:
21
07
2024
received:
28
03
2024
accepted:
12
08
2024
medline:
5
9
2024
pubmed:
5
9
2024
entrez:
5
9
2024
Statut:
aheadofprint
Résumé
Early diagnosis remains a major limitation of cancer outcomes with ethnicity and deprivation being determinants of inequalities that impact outcomes. Prostate cancer suffers from lower incidence rates and higher mortality rates in the most deprived versus the least deprived groups. We developed the 'Man Van' to enable high-risk male patients' from deprived communities and ethnic minorities increased access to health care to address these health inequalities. Between December 2021 and December 2022 the Man Van project was piloted in eight different locations chosen using geospatial targeting based on ethnic minority populations and deprivation scores. The primary outcome measures were the prevalence of prostate cancer and other health conditions. 810 men were recruited to be seen at our Man Van clinics with 610 men attending. 48% of attendees were non-White including 30% of men who were Black. 420 men had PSA tests performed with a median PSA of 1 μg/L. 15 prostate cancers were diagnosed (3.6%; 95% CI 2.0-5.9) with 10 of these being clinically significant disease. Black men were more likely to be diagnosed compared to white men: 7.1% versus 1.8% (p < .05). The Man Van project is a novel approach to tackling health inequalities combining awareness raising, improved access to healthcare as well as ease of follow-up. Comparatively high levels of prostate cancers were diagnosed at early stages and high levels of other health conditions were found which could improve the economic value of the service.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : RM Partners Cancer Alliance
Informations de copyright
© 2024 The Author(s). International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Public Health Fingertips. Public Health Outcomes Framework.
GOV.UK. English indices of deprivation. 2019.
Office for Health Improvement and Disparities. Public health profile 2023 (accessed 12 June 2023). https://fingertips.phe.org.uk.
McCaffery K, Wardle J, Nadel M, Atkin W. Socioeconomic variation in participation in colorectal cancer screening. J Med Screen. 2002;9:104‐108. doi:10.1136/jms.9.3.104
Ogunsanya ME, Brown CM, Odedina FT, Barner JC, Adedipe TB, Corbell B. Knowledge of prostate cancer and screening among Young multiethnic black men. Am J Mens Health. 2017;11:1008‐1018. doi:10.1177/1557988316689497
Hammond WP, Matthews D, Mohottige D, Agyemang A, Corbie‐Smith G. Masculinity, medical mistrust, and preventive health services delays among community‐dwelling African‐American men. J Gen Intern Med. 2010;25:1300‐1308. doi:10.1007/s11606‐010‐1481‐z
Madhav KC, Oral E, Rung AL, et al. Neighborhood deprivation and risk of mortality among men with prostate cancer: findings from a long‐term follow‐up study. Prostate. 2022;82:783‐792. doi:10.1002/pros.24320
Global Cancer Observatory: Cancer today. Lyon, France: International Agency for Research on Cancer (accessed 19 June 2023). https://gco.iarc.fr/today.
Cancer Research UK. Early diagnosis data hub. https://crukcancerintelligence.shinyapps.io/EarlyDiagnosis/.
James ND, Tannock I, N'Dow J, et al. The lancet commission on prostate cancer: planning for the surge in cases. Lancet. 2024;403:1683‐1722. doi:10.1016/S0140‐6736(24)00651‐2
Cancer Registration Statistics. Deaths from cancer increased with deprivation. 2020. https://digital.nhs.uk/data‐and‐information/publications/statistical/cancer‐registration‐statistics/england‐2020/deaths‐from‐cancer‐increased‐with‐deprivation.
National Prostate Cancer Audit. National Prostate Cancer Audit Short Report: Patient and tumour characteristics associated with metastatic prostate cancer at diagnosis in England. 2022.
Gnanapragasam VJ, Greenberg D, Burnet N. Urinary symptoms and prostate cancer—the misconception that may be preventing earlier presentation and better survival outcomes. BMC Med. 2022;20:264. doi:10.1186/s12916‐022‐02453‐7
Lloyd T, Hounsome L, Mehay A, Mee S, Verne J, Cooper A. Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008‐2010. BMC Med. 2015;13:171. doi:10.1186/s12916‐015‐0405‐5
Hugosson J, Roobol MJ, Månsson M, et al. A 16‐year follow‐up of the European randomized study of screening for prostate cancer. Eur Urol. 2019;76:43‐51. doi:10.1016/j.eururo.2019.02.009
Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380:1778‐1786. doi:10.1016/S0140‐6736(12)61611‐0
Hugosson J, Månsson M, Wallström J, et al. Prostate cancer screening with PSA and MRI followed by targeted biopsy only. N Engl J Med. 2022;387:2126‐2137. doi:10.1056/nejmoa2209454
Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI‐targeted or standard biopsy for prostate‐cancer diagnosis. N Engl J Med. 2018;378:1767‐1777. doi:10.1056/NEJMoa1801993
Newman TH, Stroman L, Hadjipavlou M, et al. EXIT from TRansrectal prostate biopsies (TREXIT): sepsis rates of transrectal biopsy with rectal swab culture guided antimicrobials versus freehand transperineal biopsy. Prostate Cancer Prostatic Dis. 2022;25:283‐287. doi:10.1038/s41391‐021‐00438‐w
Young B, Bedford L, Kendrick D, Vedhara K, Robertson JFR, das Nair R. Factors influencing the decision to attend screening for cancer in the UK: a meta‐ethnography of qualitative research. J Publ Health. 2018;40:315‐339. doi:10.1093/pubmed/fdx026
James LJ, Wong G, Craig JC, et al. Men's perspectives of prostate cancer screening: a systematic review of qualitative studies. PLoS One. 2017;12:1‐23. doi:10.1371/journal.pone.0188258
Young B, Robb KA. Understanding patient factors to increase uptake of cancer screening: a review. Future Oncol. 2021;17:3757‐3775. doi:10.2217/fon‐2020‐1078
Brancati FL, Kao WHL, Folsom AR, Watson RL, Szklo M. Incident type 2 diabetes mellitus in African American and white adults. The atherosclerosis risk in communities study. JAMA. 2000;283:2253‐2259. doi:10.1001/jama.283.17.2253
Chaturvedi N. Ethnic differences in cardiovascular disease. Heart. 2003;89:681‐686. doi:10.1136/heart.89.6.681
Spanakis EK, Golden SH. Race/ethnic difference in diabetes and diabetic complications. Curr Diab Rep. 2013;13:814‐823. doi:10.1007/s11892‐013‐0421‐9
Mensah GA, Mokdad AH, Ford ES, Greenlund KJ, Croft JB. State of disparities in cardiovascular health in the United States. Circulation. 2005;111:1233‐1241. doi:10.1161/01.CIR.0000158136.76824.04
Kurian AK, Cardarelli KM. Racial and ethnic differences in cardiovascular disease risk factors: a systematic review. Ethn Dis. 2007;17:143‐152.
NICE Guidelines Prostate Cancer. How should I assess a person with suspected prostate cancer? 2022.
Martin RM, Donovan JL, Turner EL, et al. Effect of a low‐intensity PSA‐based screening intervention on prostate cancer mortality: the CAP randomized clinical trial. JAMA. 2018;319:883‐895. doi:10.1001/jama.2018.0154
Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate‐cancer screening trial. N Engl J Med. 2009;360:1310‐1319. doi:10.1056/NEJMoa0810696
Office for National Statistics (ONS). ONS website, statistical bulletin, Ethnic group, England and Wales: Census (29 November 2022). 2021.
Rencsok EM, Bazzi LA, McKay RR, et al. Diversity of enrollment in prostate cancer clinical trials: current status and future directions. Cancer Epidemiol Biomarkers Prev. 2020;29:1374‐1380. doi:10.1158/1055‐9965.EPI‐19‐1616
Hamdy FC, Donovan JL, Lane JA, et al. Fifteen‐year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023;388:1547‐1558. doi:10.1056/NEJMoa2214122
Lane JA, Donovan JL, Davis M, et al. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. Lancet Oncol. 2014;15:1109‐1118. doi:10.1016/S1470‐2045(14)70361‐4
McClelland S III, Mitin T. The danger of applying the ProtecT trial to minority populations. JAMA Oncol. 2018;4:291. doi:10.1001/jamaoncol.2017.5452
Sundi D, Ross AE, Humphreys EB, et al. African American men with very low‐risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol. 2013;31:2991‐2997. doi:10.1200/JCO.2012.47.0302
Evans S, Metcalfe C, Ibrahim F, Persad R, Ben‐Shlomo Y. Investigating black‐white differences in prostate cancer prognosis: a systematic review and meta‐analysis. Int J Cancer. 2008;123:430‐435. doi:10.1002/ijc.23500
Shekarriz B, Tiguert R, Upadhyay J, et al. Impact of location and multifocality of positive surgical margins on disease‐free survival following radical prostatectomy: a comparison between African‐American and white men. Urology. 2000;55:899‐903. doi:10.1016/s0090‐4295(00)00463‐5
Walsh EI, Turner EL, Lane JA, et al. Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial. Trials. 2016;17:1‐6. doi:10.1186/s13063‐016‐1624‐6